Monitor Japan launch trajectory and reimbursement decisions, as well as upcoming quarterly revenue contribution from the Japan market. The PANOVA-3 overall survival data publication in JCO provides additional clinical validation for physician adoption.
Price Chart
Executive Summary
NovoCure announced that Japan's MHLW approved Optune Pax for unresectable locally advanced pancreatic cancer, based on the Phase 3 PANOVA-3 trial which met its primary endpoint of statistically significant improvement in median overall survival. This is the third major regulatory approval for Optune Pax in 2026, following FDA approval in February and CE Mark in June, expanding the addressable market into Japan where approximately 46,000 patients are diagnosed with pancreatic cancer annually.
Key Facts
- Japan's MHLW approved Optune Pax for unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel
- Approval based on Phase 3 PANOVA-3 trial which met primary endpoint of statistically significant improvement in median overall survival
- Optune Pax was previously approved by FDA in February 2026 and received CE Mark in June 2026
- Approximately 46,000 patients diagnosed with pancreatic cancer each year in Japan
- PANOVA-3 results published in Journal of Clinical Oncology
- Optune Pax was well-tolerated with 76.3% of patients experiencing device-related skin AEs, mostly Grade 1-2; 7.7% experienced Grade 3 events
Financial Impact
Japan approval opens a new market of ~46,000 annual pancreatic cancer diagnoses; no revenue guidance or deal value provided in filing
Risk Factors
- Japan pricing and reimbursement may be lower than US levels
- Competition from existing pancreatic cancer therapies in Japan
- Commercial ramp in Japan may take several quarters
- Device-related skin adverse events (76.3% incidence) could limit patient adherence
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000071 |
| Document: paxjapandecisionpr.htm | 0001645113-26-000071 |
| Document: 0001645113-26-000071-index-headers.html | 0001645113-26-000071 |
| Document: 0001645113-26-000071-index.html | 0001645113-26-000071 |
| Document: 0001645113-26-000071.txt | 0001645113-26-000071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $15.92 $14.94 | ▼ −6.16% | ▼ −6.90% | $14.62 (−8.17%) |
Sep 9, 2026 6w ago | 8-K | $15.63 $15.35 | ▼ −1.79% | ▼ −1.19% | $14.62 (−6.46%) |
Sep 1, 2026 8w ago | 8-K | $17.38 $17.83 | ▲ +2.59% | ▲ +2.15% | $14.62 (−15.88%) |
Jul 23, 2026 13w ago | 8-K | $19.99 $17.65 | ▼ −11.71% | ▼ −11.81% | $14.62 (−26.86%) |
Jun 30, 2026 17w ago | 8-K | $15.15 $15.78 | ▲ +4.16% | ▲ +4.29% | $14.62 (−3.50%) |
Jun 18, 2026 18w ago | 8-K | $14.28 $13.61 | ▲ +4.69% | ▲ +4.38% | $14.62 (−2.38%) |
Jun 5, 2026 20w ago | 8-K | $16.85 $17.24 | ▲ +2.31% | ▲ +2.61% | $14.62 (−13.23%) |
Jun 3, 2026 20w ago | Insider Cluster | $17.99 $17.16 | ▼ −4.61% | ▼ −2.04% | $14.62 (−18.73%) |
Jun 3, 2026 20w ago | Insider Cluster | $17.99 $17.16 | ▼ −4.61% | ▼ −2.02% | $14.62 (−18.73%) |
Apr 20, 2026 27w ago | DEFA14A | $12.23 $13.02 | ▲ +6.46% | ▲ +5.44% | $14.62 (+19.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers